What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His primary scientific interests are in Internal medicine, Cancer, Oncology, Cancer research and Surgery.
His research in Internal medicine intersects with topics in Gastroenterology and Gynecology.
The various areas that he examines in his Cancer study include PI3K/AKT/mTOR pathway, Disease, Pathology and Immunology.
He works mostly in the field of Oncology, limiting it down to concerns involving Head and neck cancer and, occasionally, Primary tumor.
His Cancer research research integrates issues from Carcinogenesis, Receptor, Oncogene and Cancer cell.
His Surgery research is multidisciplinary, relying on both Incidence, Epidermoid carcinoma, Leukoplakia and Hazard ratio.
His most cited work include:
- The Influence of Finasteride on the Development of Prostate Cancer (2232 citations)
- Head and neck cancer. (2109 citations)
- Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per Milliliter (2006 citations)
What are the main themes of his work throughout his whole career to date?
Scott M. Lippman mainly investigates Internal medicine, Oncology, Cancer, Cancer research and Pathology.
His Internal medicine research incorporates themes from Gastroenterology and Surgery.
The concepts of his Surgery study are interwoven with issues in Placebo and Epidermoid carcinoma.
His work carried out in the field of Oncology brings together such families of science as Clinical trial, Head and neck cancer, Gynecology, Breast cancer and Single-nucleotide polymorphism.
Scott M. Lippman interconnects Carcinoma, Disease and Immunology in the investigation of issues within Cancer.
His Cancer research study incorporates themes from Retinoid, Retinoic acid, Endocrinology, Cancer cell and Apoptosis.
He most often published in these fields:
- Internal medicine (58.24%)
- Oncology (38.83%)
- Cancer (34.64%)
What were the highlights of his more recent work (between 2012-2021)?
- Internal medicine (58.24%)
- Oncology (38.83%)
- Cancer (34.64%)
In recent papers he was focusing on the following fields of study:
Scott M. Lippman mostly deals with Internal medicine, Oncology, Cancer, Cancer research and Lung cancer.
Scott M. Lippman frequently studies issues relating to Placebo and Internal medicine.
As a part of the same scientific family, Scott M. Lippman mostly works in the field of Oncology, focusing on KRAS and, on occasion, Concordance.
His Cancer research includes themes of Precision medicine and Pathology.
His research on Cancer research also deals with topics like
- Gene which is related to area like Circulating tumor DNA,
- PI3K/AKT/mTOR pathway which intersects with area such as MAPK/ERK pathway.
His Lung cancer research includes elements of Cohort study, Quality of life, Immunology, Carcinoma and Adenocarcinoma.
Between 2012 and 2021, his most popular works were:
- Comprehensive genomic characterization of head and neck squamous cell carcinomas (1933 citations)
- An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance (577 citations)
- Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline (226 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Scott M. Lippman focuses on Cancer, Internal medicine, Cancer research, Oncology and Lung cancer.
He has included themes like Precision medicine and Gerontology in his Cancer study.
His work focuses on many connections between Internal medicine and other disciplines, such as Surgery, that overlap with his field of interest in Placebo.
The Cancer research study combines topics in areas such as Salivary duct carcinoma, Malignancy, Gene knockdown, FAT1 and CDKN2A.
Scott M. Lippman has researched Oncology in several fields, including Epidermal growth factor receptor, Survival rate, Mutation, Blockade and Prospective cohort study.
The study incorporates disciplines such as Immunology, Tamoxifen, KRAS, Targeted therapy and Primary tumor in addition to Lung cancer.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
